Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/06/22
Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 08/10/22
Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferencePRNewsWire • 05/17/22
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 05/12/22
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVTPRNewsWire • 04/30/22
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVTPRNewsWire • 04/14/22
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 03/24/22
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical OfficerPRNewsWire • 02/16/22
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual ConferencePRNewsWire • 01/04/22
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVTPRNewsWire • 11/15/21
Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 11/12/21
Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare ConferencePRNewsWire • 09/22/21
Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/07/21
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 08/11/21
Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferencePRNewsWire • 05/26/21
Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For ChinaBenzinga • 05/17/21
Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21PRNewsWire • 05/17/21
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate UpdatePRNewsWire • 05/17/21
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater ChinaPRNewsWire • 05/17/21
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 03/29/21
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular RatePRNewsWire • 03/29/21
Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 11/13/20
Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded WarrantsPRNewsWire • 10/23/20